1. Völkel V, Schatz S, Draeger T, Gerken M, Klinkhammer-Schalke M, Fürst A. Transanal total mesorectal excision: short- and long-term results of the first hundred cases of a certified colorectal cancer center in Germany. Surg Endosc. 2022 Feb;36(2):1172–80.

  2. Vener C, Rossi S, Minicozzi P, Marcos-Gragera R, Poirel HA, Maynadié M, et al. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials. Front Oncol. 2022;12:892684.

  3. van Leeuwen M, Kieffer JM, Young TE, Annunziata MA, Arndt V, Arraras JI, et al. Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. J Cancer Surviv Res Pract. 2022 Jan 27

  4. Thong MSY, Doege D, Weißer L, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study. J Cancer Res Clin Oncol. 2022 Jan;148(1):155–62.

  5. Struck JP, Schnoor M, Schulze A, Hupe MC, Ozimek T, Oppolzer IA, et al. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals. World J Urol. 2022 Feb;40(2):409–18.

  6. Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard JL, et al. Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. Lancet Child Adolesc Health. 2022 Jun;6(6):409–31.

  7. Spoerl S, Spoerl S, Reil S, Gerken M, Ludwig N, Taxis J, et al. Prognostic Value of Perineural Invasion on Survival and Recurrence in Oral Squamous Cell Carcinoma. Diagn Basel Switz. 2022 Apr 24;12(5).

  8. Spoerl S, Gerken M, Chamilos C, Spoerl S, Fischer R, Vielsmeier V, et al. Clinical significance of panendoscopy in initial staging of oral squamous cell carcinoma and detection of synchronous second malignancies of the upper aerodigestive tract - Insights from a retrospective population-based cohort study. J Cranio-Maxillo-fac Surg Off Publ Eur Assoc Cranio-Maxillo-fac Surg. 2022 Jun;50(6):515–22.

  9. Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, et al. Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors. Breast Care Basel Switz. 2022 Apr;17(2):208–23.

  10. Schmidt ME, Goldschmidt S, Hermann S, Steindorf K. Late effects, long-term problems and unmet needs of cancer survivors. Int J Cancer. 2022 Oct 15;151(8):1280–90.

  11. Scharl S, Sprötge T, Gerken M, Scharl A, Ignatov A, Inwald EC, et al. Factors influencing treatment decision and guideline conformity in high-grade endometrial cancer patients: a population-based study. Arch Gynecol Obstet. 2022 Jan;305(1):203–13.

  12. Sahm M, Schneider C, Gretschel S, Kube R, Becker A, Günther M, et al. [Reality of care of colorectal cancer in the State of Brandenburg : With special consideration of the number of hospital cases and certification as a colorectal cancer center]. Chir Z Alle Geb Oper Medizen. 2022 Mar;93(3):274–85.

  13. Röhrmoser K, Ignatov A, Gerken M, Ortmann O, Klinkhammer-Schalke M, Papathemelis T. Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration. J Cancer Res Clin Oncol. 2022 Feb 18;

  14. Roessler M, Schmitt J, Bobeth C, Gerken M, Kleihues-van Tol K, Reissfelder C, et al. Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. BMC Cancer. 2022 Jun 7;22(1):621.

  15. Pigeot I, Bongaerts B, Eberle A, Katalinic A, Kieschke J, Luttmann S, et al. [Linkage of claims data with data from epidemiological cancer registries: possibilities and limitations in the German federal states]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 May;65(5):615–23.

  16. Mantke R, Schneider C, Weylandt K, Gretschel S, Marusch F, Kube R, et al. [Epidemiology and surgical treatment of pancreatic cancer in the State of Brandenburg : Analysis of 5418 cases]. Chir Heidelb Ger. 2022 Aug;93(8):788–801.

  17. Köngeter A, Schickhardt C, Jungkunz M, Bergbold S, Mehlis K, Winkler EC. Patients’ Willingness to Provide Their Clinical Data for Research Purposes and Acceptance of Different Consent Models: Findings From a Representative Survey of Patients With Cancer. J Med Internet Res. 2022 Aug 25;24(8):e37665.

  18. Kollhorst B, Reinders T, Grill S, Eberle A, Intemann T, Kieschke J, et al. Record linkage of claims and cancer registries data-Evaluation of a deterministic linkage approach based on indirect personal identifiers. Pharmacoepidemiol Drug Saf. 2022 Sep 21;

  19. Klinkhammer-Schalke M, Wesselmann S, Bruns J, Nettekoven G, Tillack A, Follmann M, et al. [Further Development and Interoperability in Oncological Care Structures, Quality Control and Research]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2022 Nov 3;

  20. Gennari P, Tchaikovski S, Mészáros J, Gerken M, Klinkhammer-Schalke M, Toth G, et al. Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer. Gynecol Oncol. 2022 Jul;166(1):57–60.

  21. Filippini Velázquez G, Schiele S, Gerken M, Neumaier S, Hackl C, Mayr P, et al. Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer. ESMO Open. 2022 Jun;7(3):100470.

  22. Fante MA, Felsenstein M, Mayer S, Gerken M, Klinkhammer-Schalke M, Herr W, et al. All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma. Front Oncol. 2022;12:852987.

  23. Deichmann S, Dworschak O, Kulemann B, Höppner J, Bolm L, Klinkhammer-Schalke M, et al. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. Zentralbl Chir. 2022 Apr;147(2):147–54.

  24. Braun R, Klinkhammer-Schalke M, Zeissig SR, Kleihus van Tol K, Bolm L, Honselmann KC, et al. Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma-Results from the German Cancer Registry Group. Cancers. 2022 Aug 16;14(16).

  25. Bolm L, Zemskov S, Zeller M, Baba T, Roldan J, Harrison JM, et al. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT). Cancers. 2022 Feb 9;14(4).

  26. Armbrust R, Ledwon P, Von Rüsten A, Schneider C, Sehouli J. Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer-Results of a Clinical Cancer Registry Database Analysis in Germany. Cancers. 2022 Sep 24;14(19).

  27. Acs M, Halmy L, Isgandarova S, Blaj S, Gerken M, Hormann B, et al. Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Doxorubicin for 90 Minutes Versus 60 Minutes After Cytoreductive Surgery (CRS). Does the 30-Minute Difference Matter? A Comparative Study in a High Volume Centre. Anticancer Res. 2022 Feb;42(2):1019–29.

  28. Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg. 2022 Nov;407(7):3057–67.

  29. Windschüttl S, Pukrop T, Herrmann A, Lindberg-Scharf P, Heudobler D, Herr W, et al. [Development of a screening workflow to identify patient needs in an interdisciplinary oncological day clinic]. Z Evidenz Fortbild Qual Im Gesundheitswesen. 2021 Jun;163:30–7.

  30. Waldmann A, Hübner J, Katalinic A. Trends Over Time in Breast-Cancer-Specific Mortality in Germany. Dtsch Arzteblatt Int. 2021 Aug 9;118(31–32):538–9.

  31. Völkel V, Klinkhammer-Schalke M, Fürst A. Falling Mortality Thanks to Improved Treatment for Colorectal Cancer. Dtsch Arzteblatt Int. 2021 Oct 1;118(39):664.

  32. Voigtländer S, Hakimhashemi A, Inwald EC, Ortmann O, Gerken M, Klug SJ, et al. The Impact of the COVID-19 Pandemic on Cancer Incidence and Treatment by Cancer Stage in Bavaria, Germany. Dtsch Arzteblatt Int. 2021 Oct 1;118(39):660–1.

  33. Staubach P, Scharl A, Ignatov A, Ortmann O, Inwald EC, Hildebrandt T, et al. Sentinel lymph node detection by means of indocyanine green using the Karl Storz VITOM(®) fluorescence camera: a comparison between primary sentinel lymph node biopsy versus sentinel lymph node biopsy after neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2021 Jun;147(6):1813–23.

  34. Spoerl S, Spanier G, Reiter E, Gerken M, Haferkamp S, Grosse J, et al. Head and neck melanoma: outcome and predictors in a population-based cohort study. Head Face Med. 2021 Oct 22;17(1):45.

  35. Spoerl S, Gerken M, Mamilos A, Fischer R, Wolf S, Nieberle F, et al. Lymph node ratio as a predictor for outcome in oral squamous cell carcinoma: a multicenter population-based cohort study. Clin Oral Investig. 2021 Apr;25(4):1705–13.

  36. Spanier G, Ugele I, Nieberle F, Symeou L, Schmidhofer S, Brand A, et al. The predictive power of CD3(+) T cell infiltration of oral squamous cell tumors is limited to non-diabetic patients. Cancer Lett. 2021 Feb 28;499:209–19.

  37. Schmidt ME, Bergbold S, Hermann S, Steindorf K. Knowledge, perceptions, and management of cancer-related fatigue: the patients’ perspective. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2021 Apr;29(4):2063–71.

  38. Scheel K, Franke T, Weikert A, Dick M, Walter A, Zeidler J, et al. Record Linkage in Clinical Cancer Registration: Experiences and Findings from Lower Saxony. Stud Health Technol Inform. 2021 May 24;278:101–9.

  39. Scharl S, Gerken M, Sprötge T, Kronberger K, Scharl A, Ignatov A, et al. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study. Acta Oncol Stockh Swed. 2021 Jul;60(7):897–903.

  40. Scharl S, Becher C, Gerken M, Scharl A, Anapolski M, Ignatov A, et al. Is there a benefit for adjuvant radio(chemo)therapy in early cervical cancer? Results from a population-based study. Arch Gynecol Obstet. 2021 Sep;304(3):759–71.

  41. Sacchetto L, Rosso S, Comber H, Bouchardy C, Broganelli P, Galceran J, et al. Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. Int J Cancer. 2021 Jun 15;148(12):2898–905.

  42. Rudolph CES, Engholm G, Pritzkuleit R, Storm HH, Katalinic A. Survival of breast cancer patients in German-Danish border regions - A registry-based cohort study. Cancer Epidemiol. 2021 Oct;74:102001.

  43. Pruessmann J, Pursche T, Hammersen F, Katalinic A, Fischer D, Waldmann A. Conditional Disease-Free and Overall Survival of 1,858 Young Women with Non-Metastatic Breast Cancer and with Participation in a Post-Therapeutic Rehab Programme according to Clinical Subtypes. Breast Care Basel Switz. 2021 Apr;16(2):163–72.

  44. Petrova E, Wellner J, Nording AK, Braun R, Honselmann KC, Bolm L, et al. Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Group. Cancers. 2021 Dec 4;13(23).

  45. Markowiak T, Neu R, Ansari MKA, Großer C, Klinkhammer-Schalke M, Hofmann HS, et al. Surgical Cytoreduction and HITOC for Thymic Malignancies with Pleural Dissemination. Thorac Cardiovasc Surg. 2021 Mar;69(2):157–64.

  46. Markowiak T, Dakkak B, Loch E, Großer C, Klinkhammer-Schalke M, Hofmann HS, et al. Video-assisted pulmonary metastectomy is equivalent to thoracotomy regarding resection status and survival. J Cardiothorac Surg. 2021 Apr 15;16(1):84.

  47. Liu Z, Thong MSY, Doege D, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany. Br J Cancer. 2021 Sep;125(6):877–83.

  48. Liu Z, Doege D, Thong MSY, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Distress mediates the relationship between cognitive appraisal of medical care and benefit finding/posttraumatic growth in long-term cancer survivors. Cancer. 2021 Oct 1;127(19):3680–90.

  49. Lindberg-Scharf P, Steinger B, Koller M, Hofstädter A, Ortmann O, Kurz J, et al. Long-term improvement of quality of life in patients with breast cancer: supporting patient-physician communication by an electronic tool for inpatient and outpatient care. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2021 Dec;29(12):7865–75.

  50. Lillini R, Tittarelli A, Bertoldi M, Ritchie D, Katalinic A, Pritzkuleit R, et al. Water and Soil Pollution: Ecological Environmental Study Methodologies Useful for Public Health Projects. A Literature Review. Rev Environ Contam Toxicol. 2021;256:179–214.

  51. Krensel M, Petersen J, Stephan B, Katalinic A, Augustin J. Comparison of patient pathways in the early detection of skin cancer - a claims data analysis. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2021 Mar;19(3):389–98.

  52. Keim U, Gandini S, Amaral T, Katalinic A, Holleczek B, Flatz L, et al. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. Eur J Cancer Oxf Engl 1990. 2021 Dec;159:98–104.

  53. Jansen L, Kanbach J, Finke I, Arndt V, Emrich K, Holleczek B, et al. Estimation of the Potentially Avoidable Excess Deaths Associated with Socioeconomic Inequalities in Cancer Survival in Germany. Cancers. 2021 Jan 19;13(2).

  54. Jansen L, Erb C, Nennecke A, Finke I, Pritzkuleit R, Holleczek B, et al. Socioeconomic deprivation and cancer survival in a metropolitan area: An analysis of cancer registry data from Hamburg, Germany. Lancet Reg Health Eur. 2021 May;4:100063.

  55. Hübner J, Mattutat J, Katalinic A. [Years of life lost: known methods and a refined approach using the example of the most frequent causes of death in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Nov;64(11):1463–72.

  56. Hetterich M, Gerken M, Ortmann O, Inwald EC, Klinkhammer-Schalke M, Eggemann H, et al. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases. Breast Cancer Res Treat. 2021 Jun;187(3):715–27.

  57. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. Psychosocial and family-centered support among breast cancer patients with dependent children. Psychooncology. 2021 Mar;30(3):361–8.

  58. González Maldonado S, Motsch E, Trotter A, Kauczor HU, Heussel CP, Hermann S, et al. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial. Int J Cancer. 2021 Mar 1;148(5):1097–105.

  59. Girardi F, Rous B, Stiller CA, Gatta G, Fersht N, Storm HH, et al. The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). Neuro-Oncol. 2021 Oct 1;23(10):1765–76.

  60. Gieseler F, Heidenreich A, Schubert J, Frielitz F, Rehmann-Sutter C, Wörler F, et al. The role of family confidants and caregivers in the care of older cancer patients: Extending the concept of ‘shared decision-making’. Health Sci Rep. 2021 Jun;4(2):e281.

  61. Gennari P, Gerken M, Mészáros J, Klinkhammer-Schalke M, Ortmann O, Eggemann H, et al. Minimal-invasive or open approach for surgery of early cervical cancer: the treatment center matters. Arch Gynecol Obstet. 2021 Aug;304(2):503–10.

  62. Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollezcek B, et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. Eur J Cancer Oxf Engl 1990. 2021 Jul;152:18–25.

  63. Finke I, Behrens G, Maier W, Schwettmann L, Pritzkuleit R, Holleczek B, et al. Small-area analysis on socioeconomic inequalities in cancer survival for 25 cancer sites in Germany. Int J Cancer. 2021 Aug 1;149(3):561–72.

  64. Elsner SA, Salek SS, Finlay AY, Hagemeier A, Bottomley CJ, Katalinic A, et al. Validation of the German version of the Family Reported Outcome Measure (FROM-16) to assess the impact of disease on the partner or family member. Health Qual Life Outcomes. 2021 Mar 24;19(1):106.

  65. Doege D, Thong MSY, Weißer L, Koch-Gallenkamp L, Jansen L, Bertram H, et al. Health-Related Quality of Life in Very Long-Term Cancer Survivors 14-24 Years Post-Diagnosis Compared to Population Controls: A Population-Based Study. Cancers. 2021 Jun 1;13(11).

  66. Deppenwiese N, Delpy P, Lambarki M, Lablans M. ADT2FHIR - A Tool for Converting ADT/GEKID Oncology Data to HL7 FHIR Resources. Stud Health Technol Inform. 2021 Sep 21;283:104–10.

  67. Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021 Jul;22(7):1002–13.

  68. Bouvier AM, Jooste V, Sanchez-Perez MJ, Bento MJ, Rocha Rodrigues J, Marcos-Gragera R, et al. Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2021 May;53(5):639–45.

  69. Teufel A, Gerken M, Fürst A, Ebert M, Hohenthanner I, Klinkhammer-Schalke M. Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer. Eur J Cancer Oxf Engl 1990. 2020 Sep;137:148–60.

  70. Stangl S, Haas K, Eichner FA, Grau A, Selig U, Ludwig T, et al. Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease-the ‘Breast cancer care for patients with metastatic disease’ (BRE-4-MED) registry. Pilot Feasibility Stud. 2020;6:11.

  71. Spoerl S, Gerken M, Fischer R, Mamilos A, Spoerl S, Wolf S, et al. Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study. Oral Oncol. 2020 Dec;111:105009.

  72. Spanier G, Böttcher J, Gerken M, Fischer R, Roth G, Lehn P, et al. Prognostic value of perioperative red blood cell transfusion and anemia on survival and recurrence in oral squamous cell carcinoma. Oral Oncol. 2020 Aug;107:104773.

  73. Sirri E, Kieschke J, Vohmann C, Katalinic A, Nennecke A, Ressing M, et al. Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study. Int J Cancer. 2020 Sep 15;147(6):1548–58.

  74. Schmuck R, Gerken M, Teegen EM, Krebs I, Klinkhammer-Schalke M, Aigner F, et al. Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. Langenbecks Arch Surg. 2020 Feb;405(1):71–80.

  75. Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. Cancer Med. 2020 Nov;9(21):8053–61.

  76. Sant M, Meneghini E, Bastos J, Rossi PG, Guevara M, Innos K, et al. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. Breast Cancer Res Treat. 2020 Sep;183(2):439–50.

  77. Robold T, Neumeier J, Ried M, Neu R, Sziklavari Z, Grosser C, et al. [Surgical Treatment of Lung Cancer: How Has the Introduction of the 8th Edition of the TNM Classification Affected Guideline-Based Therapy?]. Zentralbl Chir. 2020 Dec;145(6):589–96.

  78. Reinert C, Gerken M, Rathberger K, Krueger K, Klinkhammer-Schalke M, Lindberg-Scharf P, et al. Single-institution cross-sectional study to evaluate need for information and need for referral to psychooncology care in association with depression in brain tumor patients and their family caregivers. BMC Psychol. 2020 Sep 10;8(1):96.

  79. Prantl L, Gerken M, Zeman F, Leitzmann M, Koller M, Klinkhammer-Schalke M, et al. Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma-An Analysis of a Certified Tumor Registry over 17 Years. J Clin Med. 2020 Apr 25;9(5).

  80. Papathemelis T, Scharl A, Anapolski M, C Inwald E, Ignatov A, Ortmann O, et al. Value of indocyanine green pelvic lymph node mapping in the surgical approach of cervical cancer. Arch Gynecol Obstet. 2020 Mar;301(3):787–92.

  81. Papathemelis T, Oppermann H, Grafl S, Gerken M, Pauer A, Scharl S, et al. Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedure. J Cancer Res Clin Oncol. 2020 Apr;146(4):961–9.

  82. Minicozzi P, Vicentini M, Innos K, Castro C, Guevara M, Stracci F, et al. Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2020 Jun;46(6):1151–9.

  83. Kowalski C, Albert US, Baumann W, Carl EG, Ernstmann N, Hermes-Moll K, et al. [DNVF Memorandum Health Services Research in Oncology]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2020 Sep;82(8–09):e108–21.

  84. Klinkhammer-Schalke M, Steinger B, Koller M, Zeman F, Fürst A, Gumpp J, et al. Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer. Eur J Cancer Oxf Engl 1990. 2020 May;130:102–13.

  85. Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hübner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer. 2020 Aug 1;147(3):709–18.

  86. Jansen L, Holleczek B, Kraywinkel K, Weberpals J, Schröder CC, Eberle A, et al. Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States. Cancers. 2020 Aug 26;12(9).

  87. Jansen L, Behrens G, Finke I, Maier W, Gerken M, Pritzkuleit R, et al. Area-Based Socioeconomic Inequalities in Colorectal Cancer Survival in Germany: Investigation Based on Population-Based Clinical Cancer Registration. Front Oncol. 2020;10:857.

  88. Hübner J, Katalinic A, Waldmann A, Kraywinkel K. Long-term Incidence and Mortality Trends for Breast Cancer in Germany. Geburtshilfe Frauenheilkd. 2020 Jun;80(6):611–8.

  89. Hellmund P, Schmitt J, Roessler M, Meier F, Schoffer O. Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000-2016. Cancers. 2020 Aug 20;12(9).

  90. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. Use of Complementary and Alternative Medicine among Young Patients with Breast Cancer. Breast Care Basel Switz. 2020 Apr;15(2):163–70.

  91. Gebauer A, Barlag H, Wesselmann S, Biedenweg L, Weitmann K, Klinkhammer-Schalke M, et al. [Evaluation of Quality Indicators of Evidence-Based Guidelines Using ADT/GEKID Base Dataset and its Organ-Specific Modules]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2020 Sep;82(8–09):710–5.

  92. Finke I, Behrens G, Schwettmann L, Gerken M, Pritzkuleit R, Holleczek B, et al. Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration. Lung Cancer Amst Neth. 2020 Apr;142:1–8.

  93. Doege D, Thong MSY, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, et al. Age-specific prevalence and determinants of depression in long-term breast cancer survivors compared to female population controls. Cancer Med. 2020 Nov;9(22):8713–21.

  94. Brunssen A, Jansen L, Eisemann N, Waldmann A, Weberpals J, Kraywinkel K, et al. Long-term relative survival from melanoma in Germany 1997-2013. Melanoma Res. 2020 Aug;30(4):386–95.

  95. Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, et al. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study. Arch Gynecol Obstet. 2020 Feb;301(2):591–602.

  96. Arndt V, Holleczek B, Kajüter H, Luttmann S, Nennecke A, Zeissig SR, et al. Data from Population-based Cancer Registration for Secondary Data Analysis: Methodological Challenges and Perspectives. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2020 Mar;82(S 01):S62–71.

  97. Wimmer T, Ortmann O, Gerken M, Klinkhammer-Schalke M, Koelbl O, Inwald EC. Adherence to guidelines and benefit of adjuvant radiotherapy in patients with invasive breast cancer: results from a large population-based cohort study of a cancer registry. Arch Gynecol Obstet. 2019 Apr;299(4):1131–40.

  98. Völkel V, Draeger T, Schnitzbauer V, Gerken M, Benz S, Klinkhammer-Schalke M, et al. Surgical treatment of rectal cancer patients aged 80 years and older-a German nationwide analysis comparing short- and long-term survival after laparoscopic and open tumor resection. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2019 Sep;45(9):1607–12.

  99. Völkel V, Draeger T, Gerken M, Fürst A, Klinkhammer-Schalke M. [Long-Term Survival of Patients with Colon and Rectum Carcinomas: Is There a Difference Between Cancer Centers and Non-Certified Hospitals?]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2019 Oct;81(10):801–7.

  100. Voelkel V, Draeger T, Groothuis-Oudshoorn CGM, de Munck L, Hueting T, Gerken M, et al. Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. J Cancer Res Clin Oncol. 2019 Jul;145(7):1823–33.

  101. Sophia Rudolph CE, Katalinic A. [Baseline Incidence of HPV-Associated Invasive and in Situ Cancers in Germany Prior to Potential Vaccination Effects]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2019 Dec;81(12):993–1000.

  102. Seliger C, Luber C, Gerken M, Schaertl J, Proescholdt M, Riemenschneider MJ, et al. Use of metformin and survival of patients with high-grade glioma. Int J Cancer. 2019 Jan 15;144(2):273–80.

  103. Rudolph C, Petersen GS, Pritzkuleit R, Storm H, Katalinic A. The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany. BMC Health Serv Res. 2019 Nov 1;19(1):786.

  104. Papathemelis T, Knobloch S, Gerken M, Scharl A, Anapolski M, Ignatov A, et al. Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer. J Cancer Res Clin Oncol. 2019 May;145(5):1369–76.

  105. Minicozzi P, Van Eycken L, Molinie F, Innos K, Guevara M, Marcos-Gragera R, et al. Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. Int J Cancer. 2019 May 1;144(9):2118–27.

  106. Hübner J, Lewin P, Pritzkuleit R, Eisemann N, Maier W, Katalinic A. Colorectal cancer screening by colonoscopy and trends in disease-specific mortality: a population-based ecological study of 358 German districts. Int J Colorectal Dis. 2019 Apr;34(4):599–605.

  107. Hübner J, Hübner F, Terheyden P, Katalinic A. [Turning point in skin cancer mortality : An analysis of the trend in Germany from 1998 to 2017]. Hautarzt Z Dermatol Venerol Verwandte Geb. 2019 Dec;70(12):989–92.

  108. Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol JEADV. 2019 Jul;33(7):1272–80.

  109. Draeger T, Völkel V, Schnitzbauer V, Gerken M, Benz S, Klinkhammer-Schalke M, et al. Laparoscopic and open resection of rectal cancer-is age an effect modifier for short- and long-term survival? Int J Colorectal Dis. 2019 May;34(5):821–8.

  110. Deck R, Babaev V, Katalinic A. [Reasons for the Non-Utilisation of an Oncological Rehabilitation. Results of a Written Survey with Patients of Oncological Healthcare Centers]. Rehabil. 2019 Aug;58(4):243–52.

  111. Brunssen A, Jansen L, Eisemann N, Waldmann A, Weberpals J, Kraywinkel K, et al. A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype. J Am Acad Dermatol. 2019 Apr;80(4):938–46.

  112. Albert US, Schreer I. [S3 guideline breast cancer: update on early detection, and mammography screening]. Radiol. 2019 Jan;59(1):13–8.

  113. Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1056–88.

  114. Völkel V, Draeger T, Gerken M, Klinkhammer-Schalke M, Fürst A. Long-term oncologic outcomes after laparoscopic vs. open colon cancer resection: a high-quality population-based analysis in a Southern German district. Surg Endosc. 2018 Oct;32(10):4138–47.

  115. Seliger C, Schaertl J, Gerken M, Luber C, Proescholdt M, Riemenschneider MJ, et al. Use of statins or NSAIDs and survival of patients with high-grade glioma. PloS One. 2018;13(12):e0207858.

  116. Scharl S, Papathemelis T, Kronberger K, Gerken M, Scharl A, Kölbl O, et al. Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. Arch Gynecol Obstet. 2018 May;297(5):1245–53.

  117. Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer Oxf Engl 1990. 2018 Mar;92:108–18.

  118. Reinert C, Rathberger K, Klinkhammer-Schalke M, Kölbl O, Proescholdt M, Riemenschneider MJ, et al. Information needs and requirements in patients with brain tumours and their relatives. J Neurooncol. 2018 Jun;138(2):407–15.

  119. Pulte D, Weberpals J, Schröder CC, Emrich K, Holleczek B, Katalinic A, et al. Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. Int J Cancer. 2018 Jul 15;143(2):324–32.

  120. Piso P, Stierstorfer K, Gerken M, Klinkhammer-Schalke M. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis. 2018 Nov;33(11):1559–67.

  121. Papathemelis T, Jablonski E, Scharl A, Hauzenberger T, Gerken M, Klinkhammer-Schalke M, et al. Sentinel Lymph Node Biopsy in Breast Cancer Patients by Means of Indocyanine Green Using the Karl Storz VITOM® Fluorescence Camera. BioMed Res Int. 2018;2018:6251468.

  122. Papathemelis T, Hassas D, Gerken M, Klinkhammer-Schalke M, Scharl A, Lux MP, et al. Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis. J Cancer Res Clin Oncol. 2018 Oct;144(10):2019–27.

  123. Ott C, Gerken M, Hirsch D, Fest P, Fichtner-Feigl S, Munker S, et al. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment. Digestion. 2018;98(3):143–52.

  124. Munker S, Gerken M, Fest P, Ott C, Schnoy E, Fichtner-Feigl S, et al. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018 Apr 23;18(1):455.

  125. Liebig-Hörl G, Puchner C, Gerken M, Klinkhammer-Schalke M, Fürst A. [Treatment strategy for early stage rectal cancer (T1 carcinoma)]. Chir Z Alle Geb Oper Medizen. 2018 May;89(5):358–64.

  126. Katalinic A. The Burden of Cancer in Germany. Dtsch Arzteblatt Int. 2018 Sep 3;115(35–36):569–70.

  127. Jobs A, Simon R, de Waha S, Rogacev K, Katalinic A, Babaev V, et al. Pneumonia and inflammation in acute decompensated heart failure: a registry-based analysis of 1939 patients. Eur Heart J Acute Cardiovasc Care. 2018 Jun;7(4):362–70.

  128. Jansen L, Buttmann-Schweiger N, Listl S, Ressing M, Holleczek B, Katalinic A, et al. Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. Oral Oncol. 2018 Jan;76:8–15.

  129. Hübner J, Waldmann A, Eisemann N, Noftz M, Geller AC, Weinstock MA, et al. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2018 Nov;27(6):563–9.

  130. Hübner J, Eisemann N, Brunßen A, Katalinic A. [Skin cancer screening in Germany: review after ten years]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Dec;61(12):1536–43.

  131. Hoebel J, Kroll LE, Fiebig J, Lampert T, Katalinic A, Barnes B, et al. Socioeconomic Inequalities in Total and Site-Specific Cancer Incidence in Germany: A Population-Based Registry Study. Front Oncol. 2018;8:402.

  132. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. [Signs of social inequality in information seeking and evaluation of information among young women with breast cancer - results of a cohort study]. Z Evidenz Fortbild Qual Im Gesundheitswesen. 2018 Dec;139:10–6.

  133. Eisemann N, Waldmann A, Holleczek B, Katalinic A. Observed and expected mortality in the German skin cancer screening pilot project SCREEN. J Med Screen. 2018 Sep;25(3):166–8.

  134. Draeger T, Völkel V, Gerken M, Klinkhammer-Schalke M, Fürst A. Long-term oncologic outcomes after laparoscopic versus open rectal cancer resection: a high-quality population-based analysis in a Southern German district. Surg Endosc. 2018 Oct;32(10):4096–104.

  135. Chen T, Brenner H, Fallah M, Jansen L, Castro FA, Geiss K, et al. Response: Methods for second primary cancers evaluation have to be standardized. Int J Cancer. 2018 Mar 15;142(6):1286–7.

  136. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, NikÅ¡ić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet Lond Engl. 2018 Mar 17;391(10125):1023–75.

  137. Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017 Apr;119(4):550–9.

  138. Weberpals J, Pulte D, Jansen L, Luttmann S, Holleczek B, Nennecke A, et al. Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21(st) century. Haematologica. 2017 Jun;102(6):e229–32.

  139. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017 Jun;18(6):719–31.

  140. Schmick A, Juergensen M, Rohde V, Katalinic A, Waldmann A. Assessing health-related quality of life in urology - a survey of 4500 German urologists. BMC Urol. 2017 Jun 19;17(1):46.

  141. Pulte D, Weberpals J, Jansen L, Luttmann S, Holleczek B, Nennecke A, et al. Survival for patients with rare haematologic malignancies: Changes in the early 21st century. Eur J Cancer Oxf Engl 1990. 2017 Oct;84:81–7.

  142. Pritzkuleit R, Eisemann N, Katalinic A. [The cartographic depiction of regional variation in morbidity : Data analysis options using the example of the small-scale cancer atlas for Schleswig-Holstein]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Dec;60(12):1319–27.

  143. Papathemelis T, Scharl S, Kronberger K, Gerken M, Scharl A, Pauer A, et al. Survival benefit of pelvic and paraaortic lymphadenectomy in high-grade endometrial carcinoma: a retrospective population-based cohort analysis. J Cancer Res Clin Oncol. 2017 Dec;143(12):2555–62.

  144. Minicozzi P, Innos K, Sánchez MJ, Trama A, Walsh PM, Marcos-Gragera R, et al. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2017 Oct;84:335–53.

  145. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017 Feb;144(2):405–13.

  146. Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017 Feb;144(2):396–404.

  147. Lindberg P, Netter P, Koller M, Steinger B, Klinkhammer-Schalke M. Breast cancer survivors` recollection of their quality of life: Identifying determinants of recall bias in a longitudinal population-based trial. PloS One. 2017;12(2):e0171519.

  148. Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, et al. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. J Invest Dermatol. 2017 Sep;137(9):1860–7.

  149. Klinkhammer-Schalke M, Steinger B, Koller M, Lindberg P. [Interventions to improve quality of life in oncological patients]. Z Evidenz Fortbild Qual Im Gesundheitswesen. 2017 May;122:48–52.

  150. Inwald EC, Ortmann O, Koller M, Zeman F, Hofstädter F, Evert M, et al. Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Res Treat. 2017 May;163(1):119–30.

  151. Hübner J, Waldmann A, Geller AC, Weinstock MA, Eisemann N, Noftz M, et al. Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma. Br J Cancer. 2017 Jan 17;116(2):253–9.

  152. Holleczek B, Katalinic A. Toward a comprehensive cancer registration in Germany. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2017 Sep;26 Joining forces for better cancer registration in Europe:S132–8.

  153. Hammersen F, Lewin P, Gebauer J, Kreitschmann-Andermahr I, Brabant G, Katalinic A, et al. Sleep quality and health-related quality of life among long-term survivors of (non-) Hodgkin lymphoma in Germany. PloS One. 2017;12(11):e0187673.

  154. Haj A, Doenitz C, Schebesch KM, Ehrensberger D, Hau P, Putnik K, et al. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center. Brain Sci. 2017 Dec 25;8(1).

  155. Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):61–6.

  156. Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, et al. Geographical variability in survival of European children with central nervous system tumours. Eur J Cancer Oxf Engl 1990. 2017 Sep;82:137–48.

  157. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur J Cancer Oxf Engl 1990. 2017 May;77:140–52.

  158. Chen T, Brenner H, Fallah M, Jansen L, Castro FA, Geiss K, et al. Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries. Int J Cancer. 2017 Dec 1;141(11):2270–80.

  159. Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review. J Am Acad Dermatol. 2017 Jan;76(1):129-139.e10.

  160. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017 May;4(5):e202–17.

  161. Sirri E, Castro FA, Kieschke J, Jansen L, Emrich K, Gondos A, et al. Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States. Pancreas. 2016 Jul;45(6):908–14.

  162. Pulte D, Jansen L, Castro FA, Krilaviciute A, Katalinic A, Barnes B, et al. Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults. Int J Cancer. 2016 Sep 15;139(6):1289–96.

  163. Pulte D, Castro FA, Jansen L, Luttmann S, Holleczek B, Nennecke A, et al. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. J Hematol OncolJ Hematol Oncol. 2016 Mar 22;9:28.

  164. Peller M, Katalinic A, Wollenberg B, Teudt IU, Meyer JE. Epidemiology of laryngeal carcinoma in Germany, 1998-2011. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2016 Jun;273(6):1481–7.

  165. Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, et al. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. Eur J Cancer Oxf Engl 1990. 2016 Jul;62:1–8.

  166. Liu L, O’Donnell P, Sullivan R, Katalinic A, Moser L, de Boer A, et al. Cancer in Europe: Death sentence or life sentence? Eur J Cancer Oxf Engl 1990. 2016 Sep;65:150–5.

  167. Katalinic A. [Improved prognosis for symptom-free older women with mammography-detected breast cancer?]. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2016 Feb;192(2):130–2.

  168. Heywang-Köbrunner SH, Schreer I, Hacker A, Noftz MR, Katalinic A. Conclusions for mammography screening after 25-year follow-up of the Canadian National Breast Cancer Screening Study (CNBSS). Eur Radiol. 2016 Feb;26(2):342–50.

  169. Eisemann N, Schnoor M, Katalinic A. Prediction of chronic lymphocytic leukaemia incidence in Germany and of patients ineligible for standard chemotherapy. Hematol Oncol. 2016 Jun;34(2):93–101.

  170. Eisemann N, Jansen L, Castro FA, Chen T, Eberle A, Nennecke A, et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol. 2016 Apr;174(4):778–85.

  171. Chen T, Fallah M, Brenner H, Jansen L, Mai EK, Castro FA, et al. Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. Sci Rep. 2016 Feb 24;6:22084.

  172. Brenner H, Schrotz-King P, Holleczek B, Katalinic A, Hoffmeister M. Declining Bowel Cancer Incidence and Mortality in Germany. Dtsch Arzteblatt Int. 2016 Feb 19;113(7):101–6.

  173. Brenner H, Castro FA, Eberle A, Emrich K, Holleczek B, Katalinic A, et al. Death certificate only proportions should be age adjusted in studies comparing cancer survival across populations and over time. Eur J Cancer Oxf Engl 1990. 2016 Jan;52:102–8.

  174. Adzersen KH, Friedrich S, Becker N. Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset. J Cancer Res Clin Oncol. 2016 Jan;142(1):167–75.

  175. Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2231–41.

  176. Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2206–16.

  177. Storm HH, Engholm G, Pritzkuleit R, Kejs AMT, Katalinic A, Dunst J, et al. Less pitfalls and variation in population based cancer survival comparisons within the European Union: Lessons from colorectal cancer patients in neighbouring regions in Denmark and Germany - The Fehmarn Belt project. Eur J Cancer Oxf Engl 1990. 2015 Jun;51(9):1188–98.

  178. Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2191–205.

  179. Rudolph C, Schnoor M, Eisemann N, Katalinic A. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2015 Aug;13(8):788–97.

  180. Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2104–19.

  181. Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B, et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol. 2015 Oct;171(2):189–96.

  182. Peters E, Anzeneder T, Jackisch C, Dimpfl T, Kunz G, Katalinic A, et al. The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up. Dtsch Arzteblatt Int. 2015 Aug 31;112(35–36):577–84.

  183. Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, et al. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematol. 2015 Nov;2(11):e481-491.

  184. Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2217–30.

  185. Lindberg P, Koller M, Steinger B, Lorenz W, Wyatt JC, Inwald EC, et al. Breast cancer survivors’ recollection of their illness and therapy seven years after enrolment into a randomised controlled clinical trial. BMC Cancer. 2015 Jul 29;15:554.

  186. Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2169–78.

  187. Klinkhammer-Schalke M, Gerken M, Barlag H, Tillack A. [Quality management in oncology supported by clinical cancer registries]. Z Evidenz Fortbild Qual Im Gesundheitswesen. 2015;109(6):452–8.

  188. Katalinic A, Eisemann N, Waldmann A. Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013. Dtsch Arzteblatt Int. 2015 Sep 18;112(38):629–34.

  189. Katalinic A. [Cancer screening-- sense or nonsense?]. Oncol Res Treat. 2015;38 Suppl 3:12.

  190. Katalinic A. [Commentary on the article ‘Skin cancer screening in Germany’ by Blum et al]. Hautarzt Z Dermatol Venerol Verwandte Geb. 2015 Jul;66(7):540–1.

  191. Jansen L, Castro FA, Gondos A, Krilaviciute A, Barnes B, Eberle A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer. 2015 Jun 1;136(11):2649–58.

  192. Holleczek B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007 - Results from the EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2158–68.

  193. Hermann S, Friedrich S, Haug U, Rohrmann S, Becker N, Kaaks R. Association between socioeconomic and demographic characteristics and utilization of colonoscopy in the EPIC-Heidelberg cohort. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2015 Mar;24(2):81–8.

  194. Haug U, Rösch T, Hoffmeister M, Katalinic A, Brenner H, Becker N. [Implementing an Organised Colorectal Cancer Screening Programme in Germany: Opportunities and Challenges]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2015 Nov;77(11):869–74.

  195. Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, et al. Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015 Apr;115(1):90–5.

  196. Gebauer J, Fick EM, Waldmann A, Langer T, Kreitschmann-Andermahr I, Lehnert H, et al. Self-reported endocrine late effects in adults treated for brain tumours, Hodgkin and non-Hodgkin lymphoma: a registry based study in Northern Germany. Eur J Endocrinol. 2015 Aug;173(2):139–48.

  197. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2130–43.

  198. Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2242–53.

  199. Fick EM, Katalinic A, Waldmann A. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany. Cancer Res Treat. 2015 Oct;47(4):747–56.

  200. Eisemann N, Waldmann A, Garbe C, Katalinic A. Development of a microsimulation of melanoma mortality for evaluating the effectiveness of population-based skin cancer screening. Med Decis Mak Int J Soc Med Decis Mak. 2015 Feb;35(2):243–54.

  201. Eisemann N, Nolte S, Schnoor M, Katalinic A, Rohde V, Waldmann A. The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. BMC Urol. 2015 Apr 10;15:28.

  202. Eberle A, Jansen L, Castro F, Krilaviciute A, Luttmann S, Emrich K, et al. Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients. Lung Cancer Amst Neth. 2015 Dec;90(3):528–33.

  203. De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2254–68.

  204. Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, et al. Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2179–90.

  205. Chen T, Fallah M, Jansen L, Castro FA, Krilavicuite A, Katalinic A, et al. Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries. Cancer Lett. 2015 Dec 1;369(1):152–66.

  206. Castro FA, Jansen L, Krilaviciute A, Katalinic A, Pulte D, Sirri E, et al. Survival of patients with gastric lymphoma in Germany and in the United States. J Gastroenterol Hepatol. 2015 Oct;30(10):1485–91.

  207. Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open. 2015 Sep 15;5(9):e008158.

  208. Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, et al. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2120–9.

  209. Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. Eur J Cancer Oxf Engl 1990. 2015 Oct;51(15):2144–57.

  210. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet Lond Engl. 2015 Mar 14;385(9972):977–1010.

  211. Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Znaor A, et al. Economic evaluation of cancer registration in Europe. J Regist Manag. 2014 Spring;41(1):31–7.

  212. Waldmann A, Anzeneder T, Katalinic A. Patients and Methods of the PATH Biobank - A Resource for Breast Cancer Research. Geburtshilfe Frauenheilkd. 2014 Apr;74(4):361–9.

  213. Schönfeld I, Kraywinkel K. [Epidemiological cancer data online: an overview of information service in Germany and Europe]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):22–6.

  214. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014 Aug;15(9):931–42.

  215. Pulte D, Jansen L, Gondos A, Katalinic A, Barnes B, Ressing M, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PloS One. 2014;9(1):e85554.

  216. Pulte D, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol. 2014 Mar;164(6):851–7.

  217. Nennecke A, Geiss K, Hentschel S, Vettorazzi E, Jansen L, Eberle A, et al. Survival of cancer patients in urban and rural areas of Germany--a comparison. Cancer Epidemiol. 2014 Jun;38(3):259–65.

  218. Kapsimalakou S, Waldmann A, Katalinic A, Grande-Nagel I, Fischer D, Barkhausen J, et al. Follow-up of probably benign lesions in non-screening breast diagnostics. Arch Gynecol Obstet. 2014 Sep;290(3):543–51.

  219. Jansen L, Eberle A, Emrich K, Gondos A, Holleczek B, Kajüter H, et al. Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. Int J Cancer. 2014 Jun 15;134(12):2951–60.

  220. Hübner J, Noftz MR, Schnoor M, Katalinic A. [Screening for colorectal, skin, breast and prostate cancer. Essential knowledge for counseling]. Internist. 2014 Oct;55(10):1171–81.

  221. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. Lancet Oncol. 2014 Jan;15(1):35–47.

  222. Eisemann N, Waldmann A, Rohde V, Katalinic A. Quality of life in partners of patients with localised prostate cancer. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2014 Jun;23(5):1557–68.

  223. Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2014 Jan;134(1):43–50.

  224. Eisemann N, Waldmann A, Katalinic A. [Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):77–83.

  225. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014 Jan;15(1):23–34.

  226. Breitbart EW, Choudhury K, Anders MP, Volkmer B, Greinert R, Katalinic A, et al. Benefits and risks of skin cancer screening. Oncol Res Treat. 2014;37 Suppl 3:38–47.

  227. Waldmann A, Schubert D, Katalinic A. Normative data of the EORTC QLQ-C30 for the German population: a population-based survey. PloS One. 2013;8(9):e74149.

  228. Waldmann A, Eisemann N, Katalinic A. Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends. Geburtshilfe Frauenheilkd. 2013 Feb;73(2):123–9.

  229. Stang A, Jansen L, Trabert B, Rusner C, Eberle A, Katalinic A, et al. Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: a high resolution study by histology and age. Cancer Epidemiol. 2013 Aug;37(4):492–7.

  230. Schnoor M, Hallof A, Hergert-Lüder D, Katalinic A, Waldmann A. [Reasons for non-participation in mammography screening--a survey in Schleswig-Holstein, Germany]. Dtsch Med Wochenschr 1946. 2013 Nov;138(45):2289–94.

  231. Rusner C, Trabert B, Katalinic A, Kieschke J, Emrich K, Stang A. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008. Cancer Epidemiol. 2013 Aug;37(4):370–3.

  232. Pulte D, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. Leuk Lymphoma. 2013 May;54(5):979–85.

  233. Pulte D, Barnes B, Jansen L, Eisemann N, Emrich K, Gondos A, et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol OncolJ Hematol Oncol. 2013 Sep 16;6(1):70.

  234. Nennecke A, Barnes B, Brenner H, Eberle A, Emrich K, Eisemann N, et al. [Data quality or differences in oncological care? - standards of reporting for cancer survival analyses based on registry data]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2013 Feb;75(2):94–8.

  235. Majek O, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, et al. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PloS One. 2013;8(7):e68077.

  236. Liu H, Hemminki K, Sundquist J, Holleczek B, Katalinic A, Emrich K, et al. Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2013 May;22(3):210–4.

  237. Liu H, Hemminki K, Sundquist J, Holleczek B, Katalinic A, Emrich K, et al. A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects. Cancer Med. 2013 Oct;2(5):718–24.

  238. Listl S, Jansen L, Stenzinger A, Freier K, Emrich K, Holleczek B, et al. Survival of patients with oral cavity cancer in Germany. PloS One. 2013;8(1):e53415.

  239. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013 Jun;139(2):539–52.

  240. Greiner F, Nolte S, Waldmann A, Katalinic A, Breitbart EW. [Collection and processing of personal data to evaluate cancer screening programmes - results of a survey of the German population in light of the bill ’early detection of cancer and cancer registries’]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2013 Nov;75(11):751–3.

  241. Gondos A, Hiripi E, Holleczek B, Luttmann S, Eberle A, Brenner H. Survival among adolescents and young adults with cancer in Germany and the United States: an international comparison. Int J Cancer. 2013 Nov;133(9):2207–15.

  242. Fick EM, Anzeneder T, Katalinic A, Waldmann A. Bisphosphonates and their Role in Therapy for Breast Cancer - Results from the PATH Biobank. Geburtshilfe Frauenheilkd. 2013 May;73(5):412–21.

  243. Eisemann N, Waldmann A, Katalinic A. Epidemiology of Breast Cancer - Current Figures and Trends. Geburtshilfe Frauenheilkd. 2013 Feb;73(2):130–5.

  244. Chen T, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2013 Jan;22(1):59–67.

  245. Waldmann A, Nolte S, Geller AC, Katalinic A, Weinstock MA, Volkmer B, et al. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. Arch Dermatol. 2012 Aug;148(8):903–10.

  246. Waldmann A, Kapsimalakou S, Katalinic A, Grande-Nagel I, Stoeckelhuber BM, Fischer D, et al. Benefits of the quality assured double and arbitration reading of mammograms in the early diagnosis of breast cancer in symptomatic women. Eur Radiol. 2012 May;22(5):1014–22.

  247. Waldmann A, Nolte S, Weinstock MA, Breitbart EW, Eisemann N, Geller AC, et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. Br J Cancer. 2012 Feb 28;106(5):970–4.

  248. Waldmann A, Adrich S, Eisemann N, Fauteck H, Grande-Nagel I, Schaefer FKW, et al. [Structure and process quality of quality-assured mamma diagnostics in Schleswig-Holstein]. ROFO Fortschr Geb Rontgenstr Nuklearmed. 2012 Feb;184(2):113–21.

  249. Schnoor M, Waldmann A, Eberle A, Holleczek B, Katalinic A. Colorectal cancer incidence in Germany: stage-shift 6 years after implementation of a colonoscopy screening program. Cancer Epidemiol. 2012 Oct;36(5):417–20.

  250. Rusner C, Bandemer-Greulich U, Engel J, Stegmaier C, Zawinell A, Holleczek B, et al. Population-based hormone receptor-specific incidence trends of breast cancer in Germany. Maturitas. 2012 Oct;73(2):152–7.

  251. Perl M, Waldmann A, Pritzkuleit R, Katalinic A. [Temporal changes in quality of life after prostate carcinoma]. Urol Ausg A. 2012 May;51(5):706–12.

  252. Majek O, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer. 2012 May 22;106(11):1875–80.

  253. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012 Nov 1;118(21):5395–402.

  254. Jansen L, Gondos A, Eberle A, Emrich K, Holleczek B, Katalinic A, et al. Cancer survival in Eastern and Western Germany after the fall of the iron curtain. Eur J Epidemiol. 2012 Sep;27(9):689–93.

  255. Hiripi E, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Survival of stomach and esophagus cancer patients in Germany in the early 21st century. Acta Oncol Stockh Swed. 2012 Sep;51(7):906–14.

  256. Hiripi E, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, et al. Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol Off J Eur Soc Med Oncol. 2012 Feb;23(2):472–9.

  257. Hertrampf K, Wiltfang J, Katalinic A, Timm O, Wenz HJ. Trends in incidence, tumour sites and tumour stages of oral and pharyngeal cancer in Northern Germany. J Cancer Res Clin Oncol. 2012 Mar;138(3):431–7.

  258. Hertrampf K, Wiltfang J, Katalinic A, Timm O, Wenz HJ. Recent trends in incidence and mortality of oral and pharyngeal cancer in Schleswig-Holstein in Northern Germany. Community Dent Health. 2012 Dec;29(4):268–73.

  259. Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, et al. Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol. 2012 Sep;167(3):606–12.

  260. Chen T, Jansen L, Gondos A, Ressing M, Holleczek B, Katalinic A, et al. Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer. 2012 Mar 30;12:128.

  261. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012 Feb;66(2):201–11.

  262. Waldmann A, Nolte S, Pritzkuleit R, Breitbart EW, Katalinic A. Different aspects of self-reported quality of life in 450 german melanoma survivors. Cancers. 2011 May 11;3(2):2316–32.

  263. Obi N, Waldmann A, Schäfer F, Schreer I, Katalinic A. Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients. Cancer Epidemiol. 2011 Jun;35(3):286–92.

  264. Obi N, Waldmann A, Babaev V, Katalinic A. [Record linkage of a large clinical practice patient cohort with the Cancer Registry Schleswig-Holstein]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2011 Jul;73(7):452–8.

  265. Hakulinen T, Arbyn M, Brewster DH, Coebergh JW, Coleman MP, Crocetti E, et al. Harmonization may be counterproductive--at least for parts of Europe where public health research operates effectively. Eur J Public Health. 2011 Dec;21(6):686–7.

  266. Eisemann N, Waldmann A, Katalinic A. Imputation of missing values of tumour stage in population-based cancer registration. BMC Med Res Methodol. 2011 Sep 19;11:129.

  267. Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet. 2011 Jul;284(1):169–74.

  268. Brenner H, Altenhofen L, Katalinic A, Lansdorp-Vogelaar I, Hoffmeister M. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. Am J Epidemiol. 2011 Nov 15;174(10):1140–6.

  269. Waldmann A, Eberle A, Hentschel S, Holleczek B, Katalinic A. [Population-based incidence rates of colorectal neoplasms (2000 - 2006) - has systematic colonoscopy screening an impact on incidence? A combined analysis of cancer registry data of the Federal States of Bremen, Hamburg, Saarland and Schleswig-Holstein]. Z Gastroenterol. 2010 Dec;48(12):1358–66.

  270. Waldmann A, Dreckschmidt J, Pritzkuleit R, Katalinic A. [Test-retest reliability of the OVIS Questionnaire--an instrument to evaluate oncological care from a patient’s point of view]. Gesundheitswesen Bundesverb Arzte Offentlichen Gesundheitsdienstes Ger. 2010 Oct;72(10):707–13.

  271. Stang A, Katalinic A, Dieckmann KP, Pritzkuleit R, Stabenow R. A novel approach to estimate the German-wide incidence of testicular cancer. Cancer Epidemiol. 2010 Feb;34(1):13–9.

  272. Schaefer FKW, Waldmann A, Katalinic A, Wefelnberg C, Heller M, Jonat W, et al. Influence of additional breast ultrasound on cancer detection in a cohort study for quality assurance in breast diagnosis--analysis of 102,577 diagnostic procedures. Eur Radiol. 2010 May;20(5):1085–92.

  273. Pritzkuleit R, Beske F, Katalinic A. [Demographic change and cancer]. Onkologie. 2010;33 Suppl 7:19–24.

  274. Katalinic A, Peters E, Beske F, Pritzkuleit R. Projection of Morbidity 2030 and 2050: Impact for the National Health System and Blood Supply. Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmedizin Immunhamatologie. 2010 Jun;37(3):155–9.